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Abstract
AIM
To determine the variability/conservation of the 
domain of hepatitis B virus (HBV) preS1 region that 
interacts with sodium-taurocholate cotransporting 
polypeptide (hereafter, NTCP-interacting domain) and 
the prevalence of the rs2296651 polymorphism (S267F, 
NTCP variant) in a Spanish population. 
METHODS
Serum samples from 246 individuals were included 
and divided into 3 groups: patients with chronic 
HBV infection (CHB) (n  = 41, 73% Caucasians), 
patients with resolved HBV infection (n  = 100, 100% 
Caucasians) and an HBV-uninfected control group (n  
= 105, 100% Caucasians). Variability/conservation 
of the amino acid (aa) sequences of the NTCP-
interacting domain, (aa 2-48 in viral genotype D) and a 
highly conserved preS1 domain associated with virion 
morphogenesis (aa 92-103 in viral genotype D) were 
analyzed by next-generation sequencing and compared 
in 18 CHB patients with viremia > 4 log IU/mL. The 
rs2296651 polymorphism was determined in all indi-
viduals in all 3 groups using an in-house real-time PCR 
melting curve analysis.
RESULTS
The HBV preS1 NTCP-interacting domain showed a 
high degree of conservation among the examined 
viral genomes especially between aa 9 and 21 (in 
the genotype D consensus sequence). As compared 
with the virion morphogenesis domain, the NTCP-
interacting domain had a smaller proportion of HBV 
genotype-unrelated changes comprising > 1% of 
the quasispecies (25.5% vs  31.8%), but a larger 
proportion of genotype-associated viral polymorphisms 
(34% vs  27.3%), according to consensus sequences 
from GenBank patterns of HBV genotypes A to H. 
Variation/conservation in both domains depended on 
viral genotype, with genotype C being the most highly 
conserved and genotype E the most variable (limited 
finding, only 2 genotype E included). Of note, proline 
residues were highly conserved in both domains, and 
serine residues showed changes only to threonine 
or tyrosine in the virion morphogenesis domain. The 
rs2296651 polymorphism was not detected in any 
participant.
CONCLUSION
In our CHB population, the NTCP-interacting domain 
was highly conserved, particularly the proline residues 
and essential amino acids related with the NTCP 
interaction, and the prevalence of rs2296651 was low/
null.
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Core tip: Simultaneous analysis of both viral and host 
features important for hepatitis B virus (HBV) entry 
into hepatocytes provided locally relevant preliminary 
information in a population previously uncharacterized 
in this regard. In-house developed next-generation 
sequencing was successfully used to investigate 
the variability of the preS1 region of the HBV large 
envelope protein, and real-time PCR melting curve 
analysis to detect the rs2296651 polymorphism (NTCP 
variant, S267F) in the HBV cellular receptor, NTCP. 
Results in a limited sample indicate that the features 
analyzed would not decrease the effectiveness of new 
therapies to block NTCP and avert HBV binding to 
hepatocytes in our particular CHB population. 
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INTRODUCTION
Hepatitis B virus (HBV) infection remains a major health 
threat, with around 240 million chronically infected 
individuals worldwide[1]. Persistently infected people 
are at high risk for the development of cirrhosis and 
hepatocellular carcinoma, and about 1 million people 
die each year due to HBV-associated liver disease[2,3]. 
Currently, the available anti-HBV treatments include 
conventional or pegylated interferon-α (IFN-α) and 
nucleos(t)ide analogs (NAs)[4]. Both types of treatments 
have drawbacks: IFN-based therapies cause significant 
side effects and yield long-term clinical benefits in less 
than 40% of treated patients[5], whereas first-line NAs 
suppress viral activity in more than 80% of patients, but 
viral eradication is rare[4,6,7].
Based on extensive research in the HBV lifecycle 
and virus-host interactions, several new agents are 
under development to achieve a functional cure 
for HBV infection[8,9]. In this sense, identification of 
sodium-taurocholate cotransporting polypeptide 
(NTCP), encoded by the SLC10A1 gene and located on 
chromosome 14[10,11], as a receptor for HBV infection[12] 
has provided valuable information for the development 
of inhibitors of HBV entry. NTCP is a multipletrans-
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membrane protein that is predominantly expressed 
at the basolateral membrane of hepatocytes. The 
primary role of NTCP is to transport bile salts from the 
portal blood into hepatocytes[10,11]. Interactions of viral 
particles with this receptor are mediated by the hepatitis 
B surface antigen (HBsAg), which is formed by three 
viral envelope proteins (large, middle, and small) that 
differ in length at the N-terminal region and share the 
same C-terminal S region[13,14]. The HBV large envelope 
proteins (LHBs), which include the preS1, preS2, and S 
regions of the surface open reading frame of the HBV 
genome, interact with NTCP through specific binding 
of a 47 amino acids (aa) domain in the N-terminal end 
of the preS1 region[15-18] (hereafter referred to as the 
NTCP-interacting domain), as is shown in Figure 1. 
It is reasonable to think that the degree of sequence 
variability in the NTCP-interacting domain, which is an 
indication of the extent to which sequence conservation 
682 February 14, 2018|Volume 24|Issue 6|WJG|www.wjgnet.com
Table 1  Demographic characteristics of the 246 patients included
Group A, CHB (n  = 41) Group B, Resolvers (n  = 100) Group C, Controls (n  = 105) P  value1
Gender, n males (%) 22 (54) 54 (54) 54 (51) NS
Age, yr, mean ± SD 54.8 ± 19.1 62.1 ± 13.0 60.3 ± 13.5 NS
Origin, n (%)
Caucasian 30 (73) 100 (100) 100 (100) -
Asian 5 (12) 0 (0) 0 (0) -
Sub-Saharan 6 (15) 0 (0) 0 (0) -
1P-value χ 2 test for gender (qualitative variable), and t-test for age (quantitative variable). CHB: Chronic hepatitis B; NS: Not statistically significant.
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Figure 1  Model of interaction between large envelope proteins and the sodium-taurocholate cotransporting polypeptide. A: Schematic diagram of hepatitis 
B virus envelope proteins: Small (S), Middle (M) and Large (L) envelope proteins. B: Representation of the interaction between the viral preS1 protein and its host 
receptor in hepatocytes, sodium-taurocholate cotransporting polypeptide (NTCP), modified from the model proposed by Urban[53]. The 2 domains analyzed in 
this study, the NTCP-interacting and virion morphogenesis (VM) domains, are indicated in the L protein. Numbering is based on the HBV genotype D consensus 
sequence. myr: Myristic acid; HBV: Hepatitis B virus.
A
B
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NTCP-interacting domain, involved in HBV entry into 
hepatocytes, and to determine the prevalence of the 
rs2296651 SNP, causing the S267F NTCP variant, in 




The study included 246 individuals recruited from 
the population attending the outpatient clinic of Vall 
Hebron University Hospital (Barcelona, Spain). The 
study was approved by the hospital ethics committee 
and all individuals gave informed written consent for 
participation at enrollment. Participants were divided 
into 3 groups: group A, patients with chronic hepatitis 
B infection (n = 41, CHB); group B, patients testing 
negative for HBsAg, but positive for antibodies against 
the hepatitis B core antigen (anti-HBc) (n = 100, 
Resolvers); and group C, an HBV-uninfected control 
group (HBsAg-negative, antiHBc-negative) (n = 105, 
Controls). Participants from groups B and C were all 
Caucasian. Ethnic heterogeneity was greater in Group 
A, with 30/41 (73%) Caucasian, 5/41 Asian (12%), 
and 6/41 sub-Saharan (15%) participants (Table 1).
Two main analyses were performed. First, the 
variability and conservation of the preS1 region of 
LHBs was analyzed in the 18 patient samples from 
Group A with a viral load greater than  > 4 logIU/mL. 
This is the sensitivity limit of the PCR to amplify that 
region. Then we determined the sequence of preS1 
by next-generation sequencing (NGS) based on 
ultra-deep pyrosequencing (UDPS) on the GS-Junior 
platform (454 Life sciences-Roche, Branford, United 
States). All 18 patients were treatment-naive and 
is important to maintain its function[19], may have an 
impact on the response to inhibitors of HBV entry based 
on synthetic myristoylated lipopeptides[20] that share the 
same aa sequence with the NTCP-interacting domain 
(i.e., therapy to block NTCP). For example, sequence 
variability in the NTCP-interacting domain might change 
its affinity to attach to NTCP, changing the dynamics of 
the competition with synthetic myristoylated lipopeptide 
analogues, and making them less effective in patients 
showing such variation. 
Furthermore, several single nucleotide poly-
morphisms (SNPs) that may change the physiological 
function of NTCP as the key transporter for bile salt 
homeostasis and affect HBV entry have been identified 
in SLC10A1[21], and most of them show an ethnicity-
dependent profile[22,23]. The rs2296651 SNP in SLC10A1 
(g.69778476G>A, GenBank accession number 
NC_000014.9), which causes the S267F variant, has 
been identified in Asian populations at a prevalence 
of 3.1% to 9.2%[22]. Previous studies focusing on 
rs2296651 and HBV infection have yielded conflicting 
results[24,25], and the role of this SNP in cirrhosis and 
hepatocellular carcinoma remains uncertain[26]. However, 
as synthetic myristoylated lipopeptides share the 
same aa sequence with the NTCP-interacting domain, 
it is reasonable to think that the presence of this SNP 
might influence the effectiveness of these therapies. 
This variant has not been found in some Caucasian 
populations (European Americans and Hispanic 
Americans)[22], but to our knowledge, there are no 
studies investigating the prevalence of rs2296651 in our 
country (Spain), where a Caucasian population mainly of 
European Mediterranean origin is prevalent.
The main aims of this study were to analyze the 
variability and conservation of the HBV preS1 region 
Table 2  Individual demographic, biochemical and virological characteristics of the 18 patients from group A (chronic hepatitis B 
patients) in whom the preS1 region was analyzed
ID Gender Age Origin HBV Genotype1 HBV DNA (logIU/mL) ALT (IU/L) HBeAg
1 Female 68 Caucasian D 5.0 29 Negative
2 Male 55 Caucasian A 5.8 46 Negative
3 Female 40 Caucasian D 4.2 29 Negative
4 Male 47 Caucasian F 5.8 88 Negative
5 Female 47 Caucasian D 6.3 170 Negative
6 Female 28 Caucasian D 5.4 22 Negative
7 Male 28 Asian C > 8 94 Positive
8 Female 41 Caucasian A 4.7 18 Negative
9 Male 39 Caucasian D 5.0 29 Negative
10 Male 45 Caucasian F > 8 51 Positive
11 Female 35 Asian C > 8 56 Positive
12 Female 46 Caucasian H 5.3 23 Negative
13 Male 37 Sub-Saharan E 4.3 37 Negative
14 Female 54 Caucasian A 4.3 21 Negative
15 Female 36 Asian C > 8 19 Positive
16 Female 20 Sub-Saharan E 5.1 22 Positive
17 Male 73 Caucasian B > 8 221 Negative
18 Male 49 Asian B 5.6 181 Negative
1HBV genotype determined by Sanger sequencing of the preS1 region (the same region as was analyzed by next-generation sequencing). ALT: Alanine 
aminotransferase; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen.
Casillas R et  al. preS1 variability and rs2296651 polymorphism
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tested negative for hepatitis D virus (HDV), hepatitis 
C virus (HCV), and human immunodeficiency virus 
(HIV). The demographic, biochemical, and virological 
characteristics of these patients are shown in Table 2. 
Second, the rs2296651 SNP (S267F) was determined 
in all 246 individuals comprising the 3 groups following 
a previously described in-house developed protocol to 
detect SNPs in human serum samples[27]. To avoid the 
discomfort of additional blood drawing, 1 mL of serum 
from samples obtained for routine clinical analysis was 
used for all analyses. 
Serological and virological determinations
Serological markers for HBV (HBsAg, HBeAg, anti-HBe, 
and anti-HBc) and anti-HCV antibodies were tested 
using commercial enzyme immunoassays mounted on 
a COBAS 8000 analyzer (Roche Diagnostics, Rotkreuz, 
Switzerland). Antibodies against HDV were tested using 
the HDV Ab kit (Dia.Pro Diagnostic Bioprobes, Sesto 
San Gioviani, Italy), and anti-HIV antibodies were 
tested by the Liaison XL murex HIV Ab/Ag kit (DiaSorin, 
Saluggia, Italy). HBV-DNA was quantified by real-
time PCR with a detection limit of 20 IU/mL (COBAS 
TaqMan HBV V2.0, Roche Diagnostics, Mannheim, 
Germany). HBV genotypes were determined by Sanger 
sequencing and phylogenetic analysis with reference 
sequences from HBV genotypes A to H of the preS1 
region (Supplementary Table 1), and supported by NGS 
analysis of the same region.
Analysis of the HBV preS1 region by NGS
In this study, we explored a fragment of the HBV 
genome including the entire preS1 region and the 
N-terminal end of preS2. The HBV genotype-specific 
insertions and deletions occurring along the HBV 
genome change the nucleotide (nt) numbering of the 
fragment. Hence, the fragment includes nt positions 
2844 to 56 (434 bp) in genotype A (genome size 3221 
nt), positions 2838 to 56 in genotypes B, C, D, E and H 
[434 bp in B, C, and H (genome size 3215 nt in all of 
Figure 2  Frequency of amino acid changes in each position in the two domains studied. In order to simplify the variations due to HBV genotype, the numeration 
of aa positions in both domains and their consensus sequences is presented according to genotype D (reference sequences obtained from GenBank, accession 
numbers provided in Supplementary Table 1). Asterisks indicate positions where the wild-type aa varies according to HBV genotype. A: Schematic diagram where the 
two regions studied are represented: the sodium-taurocholate cotransporting polypeptide (NTCP)-interacting domain from residues 2 to 48 of the N-terminal end of 
preS1, and the virion morphogenesis (VM) domain from residues 92 to 108 of the C-terminal end of preS1 and the first 5 residues from the N-terminal end of preS2. 
B: Barplot representing the frequency of aa changes (above 1% of HBV quasispecies) within each HBV genotype in the NTCP interaction and virion morphogenesis 
domains (Specific aa changes are shown in Supplementary Table 2).
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them), 401 bp in D (genome size 3182 nt), and 431 bp 
in E (genome size 3212 nt)] and positions 2837 to 56 
(434 bp) in genotype F (genome size 3215 nt).
A detailed description of the molecular amplification, 
NGS procedures carried out, and subsequent bioinformatics 
filtering of the sequencing data is provided in the Supp-
lementary Materials and Methods (Supplementary 
Protocol 1). Briefly, molecular amplification was per-
formed by nested PCR. In the final PCR products 
(amplicons), the technique incorporated M13 universal 
adaptor sequences (forward and reverse), a unique 
identifier that enabled grouping of the sequences derived 
from each sample [multiplex identifier sequences (MID)], 
and sequences A and B (adaptors for the elements of 
the UDPS system). The amplicons were purified and 
pooled at equimolecular concentrations. The pool was 
UDPS-analyzed following the manufacturer’s protocol. 
The sequencing data underwent a bioinformatics filtering 
procedure based on an in-house-developed pipeline[28], 
with all computations done in the R environment 
and language[29]. UDPS reads (sequences from each 
individual amplicon) were demultiplexed according to 
their MID sequence, and primers were trimmed. After a 
quality filter step, reads with the same nt sequence were 
collapsed into haplotypes, that is, unique sequences 
covering the full amplicon observed on the clean set of 
sequences[30]. We then selected haplotypes covering 
the full amplicon and common to both the forward 
and reverse strands whose sequences were present 
in frequencies of > 0.25% of the complete set of se-
quences.
Amino acid variability/conservation in the preS1 region
The variability/conservation of the aa sequence in the 
NTCP-interacting domain was compared to that of 
a conserved domain with a pivotal function in virion 
morphogenesis[31]. This domain, located in the preS1 
C-terminal (Figure 1), was selected for comparison 
purposes as a “sequence conservation control” because 
of its high degree of conservation in other ortho-
hepadnaviruses, such as woodchuck hepatitis virus[31].
The NTCP-interacting domain includes 47 aa from 
the N-terminal end of the preS1 region (aa 13-59 in 
HBV genotypes A, B, C, F and H, aa 2-48 in genotype 
D, and aa 12-58 in genotype E), whereas the virion 
morphogenesis domain includes 22 aa lying between 
the C-terminal end of preS1 and the first 5 aa from the 
N-terminal end of preS2 (aa 103-124 in HBV genotypes 
A, B, C, F and H, aa 92-103 in genotype D, and aa 
102-123 in genotype E).
The first step of this analysis was to classify the 
haplotypes from each patient according to their HBV 
genotype by phylogenetic analysis in order to differ-
entiate sequence variations from genotype-related 
polymorphisms. First, we selected 86 full-length HBV 
genome sequences representative of HBV genotypes 
A to H, obtained from GenBank (accession numbers in 
Supplementary Table 1) and extracted the region from 
nt 2837, 2838, or 2844 (depending on viral genotype) to 
56. We then determined the maximum genetic distances 
between sequences from the same HBV genotype in 
this region and the minimum genetic distances between 
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Figure 3  Sequence logos showing the information content of amino acid positions from the sodium-taurocholate cotransporting polypeptide-interacting 
domain and the virion morphogenesis domain, in all the haplotypes obtained by next-generation sequencing. In order to simplify variations due to HBV 
genotype, the numeration of aa positions from both domains is presented according to genotype D: NTCP-interacting domain from residues 2 to 48 of the N-terminal 
end of preS1, and the virion morphogenesis domain from residues 92 to 108 of the C-terminal end of preS1 and first 5 residues from the N-terminal end of preS2. 
Positions where the wild-type aa varies according to HBV genotype have been highlighted in bold and red. aa: Amino acid; NTCP: Sodium-taurocholate cotransporting 
polypeptide.
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sequence identity threshold. The threshold was then 
used to cluster the individual haplotypes from each 
patient; sequences with an identity above the identity 
threshold were grouped together in the same cluster 
and their frequencies were added up. The master 
sequence (the most abundant haplotype) from each 
cluster and the sequences obtained from the 86 full-
length genomes then underwent phylogenetic analysis 
to determine the HBV genotype. Genetic distances 
between master sequences and the remaining se-
quences in their clusters were below the minimum 
distance between sequences from different genotypes; 
thus, all the sequences in the cluster were considered 
to belong to the same HBV genotype as the master 
sequence. All individual haplotypes were then separated 
into different fasta files according to the genotype 
assigned to each of them and translated into aa 
sequences. The aa haplotypes with the same sequence 
were recollapsed and their frequencies were updated.
The multiple alignments of aa haplotypes obtained 
were used to detect point mutations, each of which was 
considered a separate variant, and to determine their 
abundance in the two regions studied.
Finally, an overall image of aa conservation/variation 
in preS1 for each HBV genotype was obtained by 
calculating the information content (IC) of each position. 
The IC of an aa position is related to the number of 
binary decisions (number of questions with a yes/no 
answer) required to find the correct aa in a given 
position among a set of 20 possibilities per position in 
the multiple alignment of haplotypes. For example, 
if the probabilities of finding any of the 20 aa (pa) 
were equal in a given position, the number of binary 
questions required to find the correct aa in this position 
would be log2 (20) = 4.322. However, since the different 
aa have different unknown probabilities of occurring in 
each position of the multiple alignment, an uncertainty 
measure, -∑a∈aa pa log2 (pa)[32], also known as “entropy”, 
must be added to the IC calculation. Thus the IC of 
each aa position was calculated using the following 
equation: aa (Site) = log2 (20)-∑a∈aa pa log2 (pa) If only 
one aa were found in a given position from the multiple 
alignment (maximum conservation), there would be no 
uncertainty in that position and the probability of finding 
that aa would be  20/20 thus -∑a∈aa pa log2 (pa) = 0 and 
aa = log2 (20)-0 = 4.322. On the other hand, if all aa 
had an equal possibility of occurring at a given position 
(maximum variability), the degree of uncertainty of 
that position would be the highest and the probability 
of finding any aa in that position would be 1/20 thus -∑
a∈aa pa log2 (pa) = 4.322 and aa = log2 (20)- 4.322 = 
0. These calculations in the regions of NTCP interaction 
(47 aa) and virion morphogenesis (22 aa) were also 
represented as sequence logos created using the R 
language package, motifStack[33]. 
The statistical and bioinformatics methods used in 
this study were reviewed by Dr. Josep Gregori from the 
liver disease-viral hepatitis laboratory (Vall d’Hebron 
Institut Recerca-Hospital Universitari Vall d’Hebron), 
CIBERehd and Roche Diagnostics SL.
Determination of the SLC10A1 gene rs2296651 (S267F) 
polymorphism
The rs2296651 SNP in the SLC10A1 gene, causing 
the NTCP S267F variant, was determined using a new 
in-house developed real-time PCR method based on 
fluorescence resonance energy transfer (FRET) probes, 
on the LightCycler 2.0 analyzer (Roche Diagnostics, 
Rotkreuz, Switzerland). PCR primers were designed to 
flank a 111-bp region of SLC10A1, including the SNP. 
The results obtained by this method were validated 
by direct sequencing (Sanger method) in genomic 
DNA extracted from blood in 18 samples from the 3 
groups: A (12), B (4), and C (2). A detailed explanation 
of the rs2296651 detection procedure by both real-
time PCR and Sanger sequencing is provided in the 
Supplementary Materials and Methods (Supplementary 
Protocol 2).
RESULTS
Identity threshold between sequences of the same 
HBV genotype in reference sequences from the region 
studied
In the regions from nt 2837, 2838, or 2844 (depending 
on viral genotype) to 56, extracted from the 86 full-
length HBV genome sequences representative of 
genotypes A to H, analysis of the maximum genetic 
distance in each genotype and the minimum genetic 
distance between different genotypes (data not shown) 
resulted in a sequence identity threshold between 
genotypes of 95%. Therefore, for each patient, 
haplotypes with a sequence identity > 95% were 
clustered together, and the master sequence from each 
cluster was included in the phylogenetic analysis to 
determine the HBV genotype.
preS1 variability and/or conservation
The NTCP-interacting domain (47 aa) and virion 
morphogenesis domain (22 aa) were analyzed in the 18 
patients in group A with viremia levels > 4 logIU/mL. In 
total, 118779 quality-filtered sequences were obtained 
from the samples, and a median of 5546 (1903 to 
13126, interquartile range, 3585) sequences containing 
both domains were analyzed per sample.
In general, aa residues from the NTCP-interacting 
domain were conserved within each HBV genotype 
among the different viral genomes examined. Only 
12 of 47 (25.5%) aa positions showed genotype-
unrelated changes occurring at > 1% of the HBV 
quasispecies, a somewhat lower percentage than in 
the virion morphogenesis domain (7 of 22 aa positions, 
31.8% with genotype-unrelated changes) (Figure 2B). 
Interestingly, according to the consensus sequences 
of HBV genotypes A to H of both domains, obtained 
from the 86 full-length HBV genome sequences from 
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GenBank, the virion morphogenesis domain had a lower 
percentage of aa positions with genotype-associated 
changes (viral polymorphisms) than the NTCP-inte-
racting domain (6 of 22, 27.3% vs 16 of 47, 34%, 
respectively) (Figure 2A). On analysis of conservation 
throughout the NTCP-interacting domain, we observed 
a high degree of conservation between aa positions 2 
to 21 (viral genotype D numeration), in which no aa 
changes in proportions greater than 1% were found, 
except in one genotype E patient who showed the H5Q 
variant in 11.8% of haplotypes (representing 5.9% of 
all genotype E haplotypes obtained) (Supplementary 
Table 2). Conservation was especially relevant between 
aa 9 and 21: very few changes were seen within each 
HBV genotype (none at > 1%) and wild-type aa were 
the same in the different genotypes (Figures 2 and 3).
According to the sequence logos layout, which shows 
the IC analysis for each aa position, HBV genotype C 
displayed the highest level of conservation: unaltered 
in the NTCP-interacting domain and only 1 aa change 
at position 124 in the virion morphogenesis domain 
(112 according to viral genotype D numeration), in 
the 4 patients included. HBV genotype E showed the 
highest variability, although it should be remembered 
that only 2 patients had this genotype (Supplementary 
Figure 1). HBV genotypes D and A (the most prevalent 
in our area)[34] showed moderate variability, with aa 28, 
103, and 109 being particularly variable in genotype D, 
and aa 54 and 120 (43 and 109 according to genotype 
D numeration, respectively) particularly variable in 
genotype A (Supplementary Figure 1). 
Of note, the sequence logos, including all haplotypes 
regardless of viral genotype (Figure 3) also indicated 
that proline (P) residues were highly conserved. 
Nonetheless, the P residue at position 30 of the NTCP-
interacting domain showed a change to lysine (K) 
in HBV genotype F and to threonine (T) in genotype 
H, and the P residue in position 36 changed to T in 
genotype E. Furthermore, there was a notable complete 
preservation of the five P residues located in the virion 
morphogenesis domain. Interestingly, serine residues 
(S) in this domain showed changes to T (positions 109 
and 124 in HBV genotype B and positions 98 and 113 
in genotype D) or tyrosine (Y) (position 123 in HBV 
genotype E and position 113 in genotype D) (Figure 3 
and Supplementary Figure 1); all of these have similar 
physicochemical characteristics, being the residues most 
commonly phosphorylated[35]. In general, the S residues 
of the NTCP-interacting domain were conserved within 
each viral genotype, but different aa were sometimes 
seen in this position between the different genotypes 
(Supplementary Figure 1).
Of note, 4 of our patients, harboring haplotypes 
classified into HBV genotypes A, D, E and H, showed 
a significant percentage of changes in the preS2 initial 
methionine residue (position 109 in genotype D) 
(Supplementary Table 2 and Supplementary Figure 1). 
Other relevant aa changes in the NTCP-interacting and 
virion morphogenesis domains of the patients and their 
frequencies are shown in Supplementary Table 2. 
SLC10A1 gene rs2296651 (S267F) polymorphism 
The SLC10A1 gene rs2296651 SNP (S267F) was 
determined in all 246 individuals recruited (95.53% 
Caucasian, 2% Asian, and 2.47% Sub-Saharan), which 
constituted a representative population of patients 
from the outpatient clinic of our hospital. None of them 
presented the SNP. Real-time PCR results were also 
confirmed by direct sequencing in 18 blood samples 
from the 3 groups: A (12), B (4), and C (2).
DISCUSSION
Since it was first identified as a specific receptor 
enabling HBV entry into human hepatocytes, the NTCP 
bile salt transporter has gained significant attention 
as a target in antiviral therapy for HBV and HDV 
(which share the same entry mechanism)[12,36,37]. The 
interaction between viral particles and this transporter 
is mediated by the region between aa 2 and 48 (HBV 
genotype D numeration) of the preS1 N-terminal end 
of LHBs[15-18], where aa 2 (glycine) must be bound 
to myristic acid (N-myr) for the viral particles to be 
infective[38,39]. Identification of this interaction has 
allowed the development of drugs that can block 
HBV entry by targeting NTCP[20]. An example of these 
drugs is Myrcludex-B, a synthetic myristoylated 47-aa 
lipopeptide derived from aa 2 to 48 of preS1, which 
has proven to effectively block HBV cellular entry in 
vitro[18,40], in vivo[41-43], and in patients included in clinical 
trials[44,45]. In a recent report, Tsukuda et al[46] explored 
an alternative strategy for blocking HBV entry based 
on proanthocyanidin and its analogs, which directly 
act on LHBs. Hence, inhibition of viral cellular entry is 
becoming consolidated as a viable new therapeutic 
approach against HBV infection. In this line, analysis 
of the preS1 N-terminal NTCP-interacting domain and 
the presence of the rs2296651 SNP (S267F) may be 
relevant as prognostic markers of the response to this 
new therapy because of their potential roles in the 
interaction that enables HBV to infect hepatocytes. 
To our knowledge, this is the first study in which 
the variability/conservation of the essential preS1 
NTCP-interacting domain has been investigated by 
NGS. The results show a high degree of conservation 
between preS1 aa positions 2 to 21 (HBV genotype 
D numeration): aa changes in proportions greater 
than 1% were found in a single position in only 1/18 
patients. Of note, among the 20 aa in the N-terminal 
end of preS1, wild-type aa were found to be conserved 
between positions 9 and 21 in all genotypes included. 
These observations suggest an essential function of this 
segment of preS1, which would agree with the results 
of a study by Glebe et al[17] In that report, hepatitis 
B attachment site mapping by infection-inhibiting 
amino-terminally acylated preS1-derived lipopeptides 
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highlighted the essential role of aa 9 to 18 for viral 
particle binding to NTCP. In addition, the findings from 
that study[17] indicated that aa sequences in positions 29 
to 48 would play an accessory role, a fact that seems 
to justify the more significant variability in this region 
observed in our NGS analysis. Therefore, conservation/
variability is not homogenous throughout the entire 
preS1 NTCP-interacting domain: whereas segments 
with a previously described essential role in the NTCP 
interaction show a highly conserved sequence, positions 
with accessory roles that are nonetheless needed for 
strongest blocking show greater variability. preS1 
structural simulations would be needed to help clarify 
the contribution of each segment in NTCP interactions 
and the sequence conservation requirements for their 
respective functions. 
After their translation, approximately 50% of LHBs 
undergo posttranslational topological reorientation, 
in which their N-terminal end is translocated to the 
endoplasmic reticulum lumen[47]. This gives rise to 
two types of LHBs: those in which the preS1 region 
has an external position in the viral particles and 
those in which this region has an internal position. 
Whereas the N-terminal region of external LHBs 
is involved in NTCP interactions[15], the C-terminal 
part of internal LHBs between aa 92 and 113 (HBV 
genotype D numeration) has a pivotal function in virion 
morphogenesis by directly contacting the nucleocapsid 
during viral particle budding[31]. Moreover, this latter 
domain is reported to be highly conserved among 
Orthohepadnavirus[31], a concept that is supported by 
the lower percentage of HBV genotype-associated viral 
polymorphisms in the virion morphogenesis domain 
than in the NTCP-interacting domain (27.3% vs 34%, 
respectively) in consensus sequences of genotypes A 
to H obtained from the 86 HBV genome sequences 
downloaded from GenBank. However, in the present 
study, HBV genotype-unrelated changes above 1% 
of the quasispecies were found in 25.5% of NTCP vs 
31.8% of C-terminal positions, with both domains being 
most highly conserved in genotype C and most highly 
variable in genotype E (a limited finding because this 
high variation was observed in 1 of only 2 genotype E 
patients included). Thus, while the NTCP-interacting 
domain seems to be more highly conserved within 
each genotype, the C-terminal virion morphogenesis 
domain seems more highly conserved between different 
HBV genotypes. The high proportion of conserved 
aa positions in both domains within the same viral 
genotype and between different genotypes seems to 
confirm that they conduct essential functions for HBV 
replication. Again, structural simulations would likely 
be helpful to understand the reasons for the sequence 
conservation and variability in these two domains.
Interestingly, P and S residues generally showed 
a high degree of conservation, particularly in the 
C-terminal virion morphogenesis domain. It must be 
kept in mind that P is often found at the end of the α 
helix or in turns or loops, and it contributes to protein 
folding by stabilizing these structures[48,49], thus being 
associated with essential structural protein motifs. 
Conservation of most P residues in the two preS1 
domains suggests their structural preservation, which 
would facilitate interactions between external LHBs and 
the NCTP cell receptor or between internal LHBs and 
nucleocapsids in the same manner as a lock and key. 
In the virion morphogenesis domain, in positions where 
S was the wild-type aa, we observed that changes 
with > 1% prevalence within the same HBV genotype 
or between different genotypes were either to T or 
to Y. Bearing in mind that S, T, and Y are the main 
targets for phosphorylation in eukaryotic cells[35], the 
tendency to keep these specific aa in specific positions 
of the virion morphogenesis domain suggests that 
they could be phosphorylated. This phosphorylation 
could be important for the functionality of the virion 
morphogenesis domain. Site-directed mutagenesis 
experiments, with modification of the P and S residues, 
could clarify the function of these two conserved aa in 
both the preS1 essential domains analyzed. 
In the present study, we also assessed the 
prevalence of the SLC10A1 gene SNP, rs2296651 
(S267F), in all 246 participants. The effect of this SNP on 
CHB is controversial. Most studies have reported that it is 
associated with CHB resistance, as it might interfere with 
ligand binding, thereby preventing HBV from cellular 
entry[24,26]. Nonetheless, one study has shown that 
rs2296651 is associated with enhanced HBV infection[25]. 
The prevalence of rs2296651 varies greatly between 
different ethnicities and geographic locations[22,23], being 
identified prevalently in Asian populations, with the 
highest rates in southern China and Vietnam[23]. This 
polymorphism has not been detected in Americans from 
European, African or Hispanic origins[22]. However, its 
prevalence in our area (typically classified as having an 
intermediate HBsAg prevalence)[50] where Caucasian 
populations mainly of European Mediterranean origin 
are predominant, has never been assessed. In the 
present study, rs2296651 was not found in any of 
the HBV patients or controls studied. Considering the 
substantial prevalence of this SNP in Asian populations 
where HBV infection is endemic, the low prevalence 
found in our area may be associated with the lower 
incidence of HBV infection[51]. 
Although the rs2296651 SNP seems to be absent 
in the chronic HBV-infected population attended in 
our setting, multiple SNPs in SLC10A1 have been 
found at relatively high allele frequencies in certain 
ethnic populations[21-26,52]. As an example, Ho et al[22] 
reported 6 additional ethnicity-dependent SNPs in the 5 
exonic regions of SLC10A1 (3 were non-synonymous 
and caused aa changes: I223T, I279T, K314E). The 
functionally relevant NTCP polymorphisms would be 
expected to modify bile acid homeostasis and HBV 
cellular entry; hence, it cannot be excluded that 
Caucasian individuals might have additional, still 
undescribed NTCP SNPs that could interfere with 
HBV infectivity. Therefore, further studies should be 
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performed to characterize and determine the prevalence 
of NTCP SNPs in different ethnic populations and their 
implications in NTCP function.
This study includes a representative sample of CHB 
patients attended in our center and includes most HBV 
genotypes (A to F and H). Necessarily, the number 
of patients carrying the less prevalent genotypes in 
our area was low. This limitation may have biased the 
conservation/variability findings in some genotypes 
due to individual variability in some patients, as was 
likely the case of the variability in genotype E. Thus, 
the findings should be considered preliminary, requiring 
confirmation in further studies with larger populations. 
Another potential limitation is that the NGS technology 
used in this study (ultra-deep pyrosequencing in the 
GS-Junior platform, 454/Roche) has been discontinued 
by the supplier. When the study was designed, this 
technique was selected as the best available one for 
our purposes, as it enabled inclusion of the preS1 
regions of NTCP interactions and virion morphogenesis 
in the same sequence read, using a single amplicon. A 
suitable alternative to enable future studies aimed at 
confirming and expanding the results of the present 
report, and in general to analyze the viral quasispecies, 
could be Sequencing By Synthesis technology on MiSeq 
platforms (Illumina, San Diego, United States), as this 
technique can generate sequence reads with a length 
similar to that of the fragment analyzed in this study. 
In conclusion, NGS analysis of preS1 domains in 
strains from 7 of the 8 main HBV genotypes showed 
a high degree of conservation of essential amino acids 
related with the NTCP interaction. Proline residues in 
both domains and potential phosphorylation targets 
in the virion morphogenesis domain were also highly 
conserved. Given the low to null prevalence of the 
rs2296651 SNP of the SLC10A1 gene in our patient 
population, we would not expect interference from 
NTCP in its interaction with preS1 or preS1-derived 
synthetic lipopeptide molecules. Thus, these preliminary 
results indicate that inhibition of HBV entry by NTCP 
block therapies would be a suitable treatment in our 
CHB population. 
The findings from this exploratory study are locally 
relevant as they provide preliminary information 
on a population previously uncharacterized in this 
regard. However, they have limited robustness for 
generalizations. Nonetheless, the study illustrates the 
value of NGS to investigate the variability of the preS1 
region of the LHBs, and real-time PCR melting curve 
analysis to detect the rs2296651 polymorphism causing 
S267F variant in NTCP, the HBV cellular receptor. 
Future studies with larger patient samples are needed 
to support the preS1 results and investigate additional 
NTCP polymorphisms. Finally, functional and structural 
studies will help decipher the implications of the high 




The preS1 region of the hepatitis B virus (HBV) large envelope protein interacts 
with its cellular receptor, sodium-taurocholate cotransporting polypeptide 
(NTCP), to enable HBV infectivity. Identification of this interaction has led 
to the development of drugs that can block HBV entry by targeting NTCP, 
such as synthetic myristoylated lipopeptides derived from the domain of the 
preS1 N-terminal end which interacts with NTCP (hereafter, NTCP-interacting 
domain), that can dock to this receptor, blocking the HBV entry mechanism. 
Several clinical trials are currently testing this type of HBV entry inhibitor; for 
example, Myrcludex-B. Furthermore, HBV cellular entry may also be impaired 
by the single nucleotide polymorphism (SNP) rs2296651 in the SLC10A1 
gene. This SNP causes the NTCP S267F variant, which can affect interactions 
between the receptor and viral particles. Study of these viral and host features 
may be relevant to understand the interaction of NTCP with the preS1 NTCP-
interacting domain and, reasonably, to provide an indication of the potential 
effectiveness of treatments with synthetic myristoylated lipopeptides derived 
from this domain.
Research motivation
Sequence variability in the NTCP-interacting domain might change its affinity to 
attach to NTCP, and this would alter the dynamics of competition with synthetic 
myristoylated lipopeptide inhibitors of HBV entry, potentially weakening the 
effectiveness of these treatments. The presence of the rs2296651 SNP causing 
the S267F NTCP variant could also impair the effectiveness of HBV treatment, 
as synthetic myristoylated lipopeptides have the same amino acid (aa) 
sequence as the NTCP-interacting domain. These factors could be analyzed 
in specific patient populations to determine the potential effect they may have 
on treatment with the new therapies designed to block NTCP and avert HBV 
binding to hepatocytes. This was done in the chronic hepatitis B (CHB) patient 
population of our area (Barcelona, Spain), mainly Caucasians of European 
Mediterranean origin, using robust methods that can be applied in other patient 
populations.
Research objectives
The main objectives of the study were to determine the variability/conservation 
of NTCP-interacting domain and the prevalence of the rs2296651 SNP (S267F 
NTCP variant) in chronically infected HBV patients. Using a high-throughput 
analytical protocol based on next-generation sequencing (NGS) and an in-
house developed PCR using fluorescence resonance energy transfer (FRET) 
probes, these objectives were realized in an exploratory sample of HBV 
patients from our setting. Analysis of these viral and host features could be 
relevant to understand the interactions between HBV and its receptor, and to 
determine their applicability as prognostic markers of response to treatment 
strategies based on NTCP blocking.
Research methods
We performed two main analyses in serum samples from 246 individuals in 
3 groups: patients with CHB, patients with resolved HBV infection, and HBV-
uninfected individuals. First, the variability/conservation of aa sequences in 
the NTCP-interacting domain was analyzed and compared to that of a highly 
conserved preS1 C-terminal domain associated with virion morphogenesis. 
Comparison between the NTCP-interacting domain and the highly conserved 
virion morphogenesis domain gave an idea of the magnitude of sequence 
conservation of the former. To perform this analysis, we developed a high-
throughput protocol based on NGS. The raw sequencing data obtained 
underwent a bioinformatics filtering and analysis procedure based on an in-
house-developed pipeline with all computations done in R environment and 
language. The conservation/variation of these sequences was analyzed by 
calculating the information content of each position, which was represented 
graphically using sequence logos, as explained in detail in the Materials and 
Methods section of the main article.
   Second, to estimate the prevalence of the rs2296651 polymorphism in our 
patient population, this SNP was determined in all samples from the patients 
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included. To accomplish this aim we designed a new in-house real-time PCR 
method based on FRET probes.
Research results
High-throughput NGS analysis yielded viral sequences for most HBV genotypes 
(A to F and H). In general, the NTCP-interacting domain showed a high degree 
of conservation, which depended on viral genotype, particularly the sequence 
between aa 9 to 21. In comparison to the virion morphogenesis domain, the 
NTCP-interacting domain showed a smaller percentage of HBV genotype-
unrelated changes, but greater variability between different HBV genotypes, 
according to consensus sequences from the GenBank patterns of genotypes 
A to H. Interestingly, proline residues showed a high degree of conservation 
in both domains, and serine residues were also particularly conserved in the 
virion morphogenesis domain, where changes above 1% of the quasispecies 
were always to potentially phosphorylatable aa. Finally, we demonstrated a low 
to null prevalence of the rs2296651 SNP in HBV patients from our area. The 
high degree of conservation of the NTCP-interacting and virion morphogenesis 
domains should to be confirmed in larger patient series, and the role of proline 
and potentially phosphorylatable residues and their implications on HBV activity 
should be clarified. The potential effect of additional NTCP polymorphisms on 
interactions between HBV and this receptor should also be investigated. 
Research conclusions
This study describes high-throughput NGS analysis of the preS1 NTCP-
interacting domain, which showed overall high conservation that depended 
on HBV genotype, particularly between aa 9 to 21. These findings concur 
with previous in vitro results demonstrating that these aa are essential for 
HBV infectivity. In the comparison with the virion morphogenesis domain, we 
focused on the proline and serine residues in the two domains: proline showed 
a high degree of conservation and changes in > 1% of the quasispecies in 
serine residues were always to potentially phosphorylatable aa in the virion 
morphogenesis domain. Based on the physical-chemical properties of these 
aa, we hypothesized that proline residues could stabilize the structure of 
these two preS1 domains, and the tendency to keep phosphorylatable aa in 
specific positions of the virion morphogenesis domain suggested that they 
may be phosphorylated. In addition, we developed an in-house real-time 
PCR method that allowed us to estimate the prevalence of the rs2296651 
SNP in our HBV patients, which turned out to be low to null. Bearing in mind 
that rs2296651 is reported to be prevalent in Asian populations, where HBV 
infection is endemic, we hypothesized that the low presence of this SNP in 
our area may be associated with the lower incidence of HBV infection. Taken 
together, the findings from this exploratory study suggest that inhibition of HBV 
entry by NTCP block therapies would be suitable treatment in our CHB patient 
population.
Research perspectives
The present study illustrates the value of NGS to investigate the variability/
conservation of the preS1 region of the LHBs. The reasons for the high degree 
of sequence conservation of the NTCP-interacting and virion morphogenesis 
domains should be investigated by preS1 structural simulations and site-
directed mutagenesis experiments, in particular with modification of the proline 
and serine phosphorylatable residues. However, it should be borne in mind that 
the sequence conservation results found in both domains should be confirmed 
in larger patient samples. In addition, the new in-house real-time PCR method 
based on FRET probes used here provided fast, reliable detection of the 
rs2296651 SNP in serum samples of all patients, and revealed a low to null 
prevalence of this SNP in our patient population. Nonetheless, it cannot be 
excluded that Caucasian individuals might have additional functionally relevant 
NTCP SNPs, which would be expected to modify bile acid homeostasis and 
HBV cellular entry. Therefore, further studies should be performed to determine 
the prevalence of NTCP SNPs in different populations, and characterize their 
implications in NTCP function.
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